Q32 Bio Completes Enrollment in the SIGNAL-AD Phase 2 Trial of Bempikibart in AD
Enrollment is complete in Q32 Bio Inc.’s SIGNAL-AD Phase 2 clinical trial of bempikibart (ADX-914) for the treatment of persistent, moderate-to-severe atopic dermatitis (AD). Bempikibart is a fully human anti-interleukin (IL)-7Rα antibody that is designed to re-regulate adaptive immune function by blocking IL-7 and TSLP signaling, both of which contribute to inflammation and injury in […]